.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Rimegepant is a small-molecule CGRP receptor antagonist that offers an oral alternative to triptan therapy for acute migraine. In this randomized, double-blind, placebo-controlled trial, adults treated a single moderate or severe migraine attack with rimegepant 75 mg or placebo. The coprimary endpoints were freedom from pain and freedom from the patient's most bothersome associated symptom at two hours. The study demonstrated superior efficacy for rimegepant on the prespecified acute-treatment outcomes, while tolerability was generally favourable. The clinical relevance is greatest for patients who need a non-triptan option or who cannot tolerate or appropriately use vasoconstrictive agents. The study also fits the broader evolution of migraine treatment toward mechanism-specific acute therapy. For HCPs, treatment selection should still consider attack frequency, nausea and vomiting, cardiovascular profile, interactions and the distinction between acute and preventive therapy. Rimegepant is not a reason to abandon behavioural strategies or preventive treatment when attacks are frequent. Rather, it broadens the therapeutic toolkit for individualised migraine care. The trial adds controlled evidence to the growing role of CGRP-pathway therapies highlighted in the IANCON programme.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Rimegepant is a small-molecule CGRP receptor antagonist that offers an oral alternative to triptan therapy for acute migraine. In this randomized, double-blind, placebo-controlled trial, adults treated a single moderate or severe migraine attack with rimegepant 75 mg or placebo. The coprimary endpoints were freedom from pain and freedom from the patient's most bothersome associated symptom at two hours. The study demonstrated superior efficacy for rimegepant on the prespecified acute-treatment outcomes, while tolerability was generally favourable. The clinical relevance is greatest for patients who need a non-triptan option or who cannot tolerate or appropriately use vasoconstrictive agents. The study also fits the broader evolution of migraine treatment toward mechanism-specific acute therapy. For HCPs, treatment selection should still consider attack frequency, nausea and vomiting, cardiovascular profile, interactions and the distinction between acute and preventive therapy. Rimegepant is not a reason to abandon behavioural strategies or preventive treatment when attacks are frequent. Rather, it broadens the therapeutic toolkit for individualised migraine care. The trial adds controlled evidence to the growing role of CGRP-pathway therapies highlighted in the IANCON programme.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
